Apellis Pharmaceuticals, Inc. 1JK.F Stock
Apellis Pharmaceuticals, Inc. Price Chart
Apellis Pharmaceuticals, Inc. 1JK.F Financial and Trading Overview
| Apellis Pharmaceuticals, Inc. stock price | 52.95 EUR |
| Previous Close | 82.5 EUR |
| Open | 80.5 EUR |
| Bid | 80.5 EUR x N/A |
| Ask | 83 EUR x N/A |
| Day's Range | 80.5 - 80.5 EUR |
| 52 Week Range | 40.16 - 87.5 EUR |
| Volume | 6 EUR |
| Avg. Volume | 20 EUR |
| Market Cap | 9.37B EUR |
| Beta (5Y Monthly) | 1.245422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.15 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.81 EUR |
1JK.F Valuation Measures
| Enterprise Value | 8.95B EUR |
| Trailing P/E | N/A |
| Forward P/E | -13.416667 |
| PEG Ratio (5 yr expected) | -0.23 |
| Price/Sales (ttm) | 88.53578 |
| Price/Book (mrq) | 22.695236 |
| Enterprise Value/Revenue | 84.481 |
| Enterprise Value/EBITDA | -13.997 |
Trading Information
Apellis Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.245422 |
| 52-Week Change | 112.92% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 87.5 EUR |
| 52 Week Low | 40.16 EUR |
| 50-Day Moving Average | 76.28 EUR |
| 200-Day Moving Average | 59.32 EUR |
1JK.F Share Statistics
| Avg. Volume (3 month) | 20 EUR |
| Avg. Daily Volume (10-Days) | 15 EUR |
| Shares Outstanding | 116.46M |
| Float | 88.6M |
| Short Ratio | N/A |
| % Held by Insiders | 13.98% |
| % Held by Institutions | 88.61% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -605.077% |
| Gross Margin | 70.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.69% |
| Return on Equity (ttm) | -158.061% |
Income Statement
| Revenue (ttm) | 105.89M EUR |
| Revenue Per Share (ttm) | 0.96 EUR |
| Quarterly Revenue Growth (yoy) | 211.79% |
| Gross Profit (ttm) | 69.79M EUR |
| EBITDA | -639102016 EUR |
| Net Income Avi to Common (ttm) | -691014976 EUR |
| Diluted EPS (ttm) | -5.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 774.12M EUR |
| Total Cash Per Share (mrq) | 6.65 EUR |
| Total Debt (mrq) | 111.87M EUR |
| Total Debt/Equity (mrq) | 27.15 EUR |
| Current Ratio (mrq) | 6.883 |
| Book Value Per Share (mrq) | 3.547 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -579804992 EUR |
| Levered Free Cash Flow (ttm) | -349684864 EUR |
Profile of Apellis Pharmaceuticals, Inc.
| Country | Germany |
| State | MA |
| City | Waltham |
| Address | 100 Fifth Avenue |
| ZIP | 02451 |
| Phone | 617 977 5700 |
| Website | https://www.apellis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 767 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Q&A For Apellis Pharmaceuticals, Inc. Stock
What is a current 1JK.F stock price?
Apellis Pharmaceuticals, Inc. 1JK.F stock price today per share is 52.95 EUR.
How to purchase Apellis Pharmaceuticals, Inc. stock?
You can buy 1JK.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Apellis Pharmaceuticals, Inc.?
The stock symbol or ticker of Apellis Pharmaceuticals, Inc. is 1JK.F.
Which industry does the Apellis Pharmaceuticals, Inc. company belong to?
The Apellis Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Apellis Pharmaceuticals, Inc. have in circulation?
The max supply of Apellis Pharmaceuticals, Inc. shares is 120.58M.
What is Apellis Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Apellis Pharmaceuticals, Inc. PE Ratio is now.
What was Apellis Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Apellis Pharmaceuticals, Inc. EPS is -4.15 EUR over the trailing 12 months.
Which sector does the Apellis Pharmaceuticals, Inc. company belong to?
The Apellis Pharmaceuticals, Inc. sector is Healthcare.